Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene

Cancer Research

Volumn 57, Issue 21, 1997, Pages 4830-4837

  Chen, Ling ^a,b   Yu, Li J ^a,c   Waxman, David J ^a  

^a BOSTON UNIVERSITY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 REDUCTASE; DIPHENYLENEIODONIUM CHLORIDE; FLAVOPROTEIN; METYRAPONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME ANALYSIS; FEMALE; GENE THERAPY; GENE TRANSFER; GROWTH INHIBITION; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RAT;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL COMMUNICATION; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 CYP2B1; FEMALE; GENE THERAPY; GENETIC VECTORS; GLIOSARCOMA; METYRAPONE; NADH, NADPH OXIDOREDUCTASES; NADPH-FERRIHEMOPROTEIN REDUCTASE; NEOPLASM PROTEINS; PRODRUGS; RATS; RATS, INBRED F344; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 0030810198     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Roth, J. A., and Cristiano, R. J. Gene therapy for cancer: what have we done and where are we going? J. Natl. Cancer Inst. (Bethesda), 89: 21-39, 1997.
2. Rosenfeld, M. E., and Curiel, D. T. Gene therapy strategies for novel cancer therapeutics. Curr. Opin. Oncol., 8: 72-77, 1996.
3. Moolten, F. L. Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther., 1: 279-287, 1994.
4. Freeman, S. M., Whartenby, K. A., Freeman, J. L., Abboud, C. N., and Marrogi, A. J. In situ use of suicide genes for cancer therapy. Semin. Oncol., 23: 31-45, 1996.
5. Moolten, F. L., and Wells, J. M. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J. Natl. Cancer Inst. (Bethesda), 82: 297-300, 1990.
6. Ezzeddine, Z. D., Martuza, R. L., Platika, D., Short, M. P., Malick, A., Choi, B., and Breakefield, X. O. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol., 3: 608-614, 1991.
7. Mullen, C. A., Kilstrup, M., and Blaese, R. M. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc. Natl. Acad. Sci. USA, 89: 33-37, 1992.
8. Huber, B. E., Austin, E. A., Good, S. S., Knick, V. C., Tibbels, S., and Richards, C. A. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res., 53: 4619-4626, 1993.
9. Mullen, C. A., Coale, M. M., Lowe, R., and Blaese, R. M. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild-type tumor. Cancer Res., 54: 1503-1506, 1994.
10. Caruso, M., Panis, Y., Gagandeep, S., Houssin, D., Salzmann, J. L., and Klatzmann, D. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc. Natl. Acad. Sci. USA, 90: 7024-7028, 1993.
11. O'Malley, B. W., Jr., Cope, K. A., Chen, S. H., Li, D., Schwartz, M. R., and Woo, S. L. C. Combination gene therapy for oral cancer in a murine model. Cancer Res., 56: 1737-1741, 1996.
12. Rainov, N. G., Kramm, C. M., Aboody-Guterman, K., Chase, M., Ueki, K., Louis, D. N., Harsh IV, G. R., Chiocca, E. A., and Breakefield, X. O. Retrovirus-mediated gene therapy of experimental brain neoplasms using the herpes simplex virus-thymidine kinase/ganciclovir paradigm. Cancer Gene Ther., 3: 99-106, 1996.
13. Trinh, Q. T., Austin, E. A., Murray, D. M., Knick, V. C., and Huber, B. E. Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res., 55: 4808-4812, 1995.
14. Link, C. J., Jr., Moorman, D., Seregina, T., Levy, J. P., and Schabold, K. J. A Phase I trial of in vivo gene therapy with the herpes simplex thymidine kinase/ganciclovir system for the treatment of refractory or recurrent ovarian cancer. Hum. Gene Ther., 7: 1161-1179, 1996.
15. Eck, S. L., Alavi, J. B., Alavi, A., Davis, A., Hackney, D., Judy, K., Mollman, J., Phillips, P. C., Wheeldon, E. B., and Wilson, J. M. Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a Phase I trial. Hum. Gene Ther., 7: 1465-1482, 1996.
16. Sladek, N. E. Metabolism of oxazaphosphorines. Pharmacol. Ther., 37: 301-355, 1988.
17. Peters, W. P., Ross, M., Vredenburgh, J. J., Meisenberg, B., Marks, L. B., Winer, E., Kurtzberg, J., Bast, R. C., Jr., Jones, R., and Shpall, E. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J. Clin. Oncol., 11: 1132-1143, 1993.
18. Ayash, L. J., Wright, J. E., Tretyakov, O., Gonin, R., Elias, A., Wheeler, C., Eder, J. P., Rosowsky, A., Amman, K., and Frei, E. I. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J. Clin. Oncol., 10: 995-1000, 1992.
19. Goren, M. P., Wright, R. K., Pratt, C. B., and Pell, F. E. Dechloroethylation of ifosfamide and neurotoxicity. Lancet, 2: 1219-1220, 1986.
20. Thigpen, T. Ifosfamide-induced central nervous system toxicity. Gynecol. Oncol., 42: 191-192, 1991.
21. Chen, L., and Waxman, D. J. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res., 55: 581-589, 1995.
22. Wei, M. X., Tamiya, T., Chase, M., Boviatsis, E. J., Chang, T. K. H., Kowall, N. W., Hochberg, F. H., Waxman, D. J., Breakefield, X. O., and Chiocca, E. A. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum. Gene Ther., 5: 969-978, 1994.
23. Clarke, L., and Waxman, D. J. Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation. Cancer Res., 49: 2344-2350, 1989.
24. Weber, G. F., and Waxman, D. J. Activation of the anti-cancer drug ifosfamide by rat liver microsomal P450 enzymes. Biochem. Pharmacol, 45: 1685-1694, 1993.
25. Chen, L., Waxman, D. J., Chen, D., and Kufe, D. W. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Cancer Res., 56: 1331-1340, 1996.
26. Manome, Y., Wen, P. Y., Chen, L., Tanaka, T., Dong, Y., Yamazoe, M., Hirshowitz, A., Kufe, D. W., and Fine, H. A. Gene therapy for malignant gliomas using replication incompetent retroviral and adenoviral vectors encoding the cytochrome P450 2B1 gene together with cyclophosphamide. Gene Ther., 3: 513-520, 1996.
27. Porter, T. D., Beck, T. W., and Kasper, C. B. NADPH-cytochrome P450 oxidoreductase gene organization correlates with structural domains of the protein. Biochemistry, 29: 9814-9818, 1990.
28. O'Leary, K. A., Beck, T. W., and Kasper, C. B. NADPH cytochrome P450 oxidoreductase gene: identification and characterization of the promoter region. Arch. Biochem. Biophys., 310: 452-459, 1994.
29. Porter, T. D. An unusual yet strongly conserved flavoprotein reductase in bacteria and mammals. Trends Biochem. Sci., 16: 154-158, 1991.
30. Strobel, H. W., Hodgson, A. V., and Shen, S. NADPH cytochrome P450 reductase and its structural and functional domains. In: P. R. Ortiz de Montellano (ed.). Cytochrome P450: structure, mechanism, and biochemistry. Ed. 2, pp. 225-244. New York: Plenum Press, 1995.
31. Vermilion, J. L., Ballou, D. P., Massey, V., and Coon, M. J. Separate roles for FMN and FAD in catalysis by liver microsomal NADPH-cytochrome P450 reductase. J. Biol. Chem., 256: 266-277, 1981.
32. Waxman, D. J., Morrissey, J. J., and LeBlanc, G. A. Hypophysectomy differentially alters P-450 protein levels and enzyme activities in rat liver: pituitary control of hepatic NADPH cytochrome P-450 reductase. Mol. Pharmacol., 35: 519-525, 1989.
33. Miwa, G. T., West, S. B., and Lu, A. Y. H. Studies on the rate-limiting enzyme component in the microsomal monooxygenase system. Incorporation of purified NADPH cytochrome c-reductase and cytochrome P450 into rat liver microsomes. J. Biol. Chem., 253: 1921-1929, 1978.
34. Cawley, G. F., Batie, C. J., and Backes, W. L. Substrate-dependent competition of different P450 isozymes for limiting NADPH-cytochrome P450 reductase. Biochemistry. 34: 1244-1247, 1995.
35. Barker, M., Hoshino, T., Gurcay, O., Wilson, C. B., Nielsen, S. L., Downie, R., and Eliason, J. Development of an animal brain tumor model and its response 10 therapy with 1,3-bis-(2-chloroethyl)-1-nitrosourea. Cancer Res., 33: 976-986, 1973.
36. Scudiero, D. A., Shoemaker, R. H., Paull, K. D., Monks, A., Tierney, S., Nofziger, T. H., Currens, M. J., Seniff, D., and Boyd, M. R. Evaluation of a soluble tetrazolium/ formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res., 48: 4827-4833, 1988.
37. Chang, T. K. H., Weber, G. F., Crespi, C. L., and Waxman, D. J. Differential activation of cyclophosphamide and ifosfamide by cytochromes P450 2B and 3A in human liver microsomes. Cancer Res., 53: 5629-5637, 1993.
38. Graham, F. L., and Prevec, L. Manipulation of adenovirus vectors. In:, E. J. Murray (ed.). Methods in Molecular Biology: Gene Transfer and Expression Protocols, Vol. 7, pp. 109-127. Clifton, NJ: The Human Press, Inc., 1991.
39. Waxman, D. J. Rat hepatic P450IIA and P450IIC subfamily expression using catalytic, immunochemical, and molecular probes. Methods Enzymol., 206: 249-267, 1991.
40. Waxman, D. J., and Walsh, C. Phenobarbital-induced rat liver cytochrome P450. Purification and characterization of two closely related isozymic forms. J. Biol. Chem. 257: 10446-10457, 1982.
41. Ram, P. A., and Waxman, D. J. Thyroid hormone stimulation of NADPH P450 reductase expression in liver and extrahepalic tissues. Regulation by multiple mechanisms. J. Biol. Chem., 267: 3294-3301, 1992.
42. Lemaire, P., and Livingstone, D. R. Inhibition studies on the involvement of fla-voprotein reductases in menadione-and nitrofurantoin-stimulated oxyradical production by hepatic microsomes of flounder (Platichthys flesus). J. Biochem. Toxicol., 9: 87-95, 1994.
43. Tew, D. G. Inhibition of cytochrome P450 reductase by the diphenyliodonium cation. Kinetic analysis and covalent modifications. Biochemistry, 32: 10209-10215, 1993.
44. McGuire, J. J., Anderson, D. J., and Bennett, B. M. Inhibition of the biotransformation and pharmacological actions of glyceryl trinitrate by the flavoprotein inhibitor, diphenyleneiodonium sulfate. J. Pharmacol. Exp. Ther., 271: 708-714, 1994.
45. Gonzalez, F. J., and Kasper, C. B. Sequential translocation of two phenobarbital-induced polysomal messenger ribonucleic acids from the nuclear envelope to the endoplasmic reticulum. Biochemistry. 20: 2292-2298, 1981.
46. Waxman, D. J., Dannan, G. A., and Guengerich, F. P. Regulation of rat hepatic cytochrome P-450: age-dependent expression, hormonal imprinting, and xenobiotic inducibility of sex-specific isoenzymes. Biochemistry, 24: 4409-4417, 1985.
47. Morgan, R. A., Couture, L., Elroy-Stein, O., Ragheb, J., Moss, B., and Anderson, W. F. Retroviral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy. Nucleic Acids Res., 20: 1293-1299, 1992.
48. Tahara, H., Zitvogel, L., Storkus, W. J., Zeh, H. J., III, McKinney, T. G., Schreiber, R. D., Gubler, U., Robbins, P. D., and Lotze, M. T. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J. Immunol., 154: 6466-6474, 1995.
49. Fisher, C. W., Shet, M. S., Caudle, D. L., Martin-Wixtrom, C. A., and Estabrook, R. W. High-level expression in Escherichia coli of enzymatically active fusion proteins containing the domains of mammalian cytochromes P450 and NADPH-P450 reductase flavoprotein. Proc. Natl. Acad. Sci. USA. 89: 10817-10821, 1992.
50. Yabusaki, Y. Artificial P450/reductase fusion enzymes: what can we learn from their structures? Biochimie, 77: 594-603, 1995.